Abiomed (ABMD) Tops Q2 EPS by 44c

Abiomed (NASDAQ: ABMD) reported Q2 EPS of $1.36, $0.44 better than the analyst estimate of $0.92. Revenue for the quarter came in at $209.8 million versus the consensus estimate of $198.93 million.

GUIDANCE:

Abiomed sees Q3 2021 revenue of $221-230 million, versus the consensus of $235.1 million.

• For full-year 2020, Baxter expects sales growth compared to the prior-year period to be up low single digits on a reported, constant currency and operational basis. The company expects U.S. GAAP earnings of $2.41 to $2.44 per share and adjusted earnings, before special items, of $3.02 to $3.05 per share. This outlook assumes, among other things, low double digit declines in hospital admissions and mid-single digit declines in surgical volumes in the fourth quarter 2020 as compared to pre-COVID levels.

For earnings history and earnings-related data on Abiomed (ABMD) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance